Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT06101901
Starting soon Observational

Revealing Engagement Dynamics Among Diabetic Kidney Disease Patients

NCT06101901 · tracked via the Priya Life Science USA tracker
Sponsor
Power Life Sciences Inc
Phase
Observational
Started
2024-11
Last updated
2023-10-26

Condition(s) studied

Diabetic Kidney Disease

Study summary

The study intends to investigate the personal experiences of diabetic kidney disease patients who take part in a separate clinical study including a specific medication intervention. The major focus will be on closely following individuals' rates of trial completion and withdrawal.

The data collected from this study will help improve future outcomes for all diabetic kidney disease as well as those in under-represented demographic groups.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients diagnosed with diabetic kidney disease * Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed * Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination. Exclusion Criteria: * Refusal of consent * Women of childbearing potential without a negative pregnancy test; or women who are lactating. * Any serious and/or unstable pre-existing medical disorders

Primary outcome measure(s)

  • Number of patients who decide to enroll in a diabetic kidney disease clinical research — 3 months
  • Rate of patients who remain in a diabetic kidney disease clinical trial to trial completion — 12 months

Trial sites (1)

FacilityCityRegionStatus
Power Life Sciences San Francisco California

More Power Life Sciences Inc. trials in the USA

Investigative Analysis of Soft Tissue Sarcoma Clinical Trials: An Observational Study Starting soon
Revealing Engagement Patterns Among Hepatic Encephalopathy Patients Starting soon
Understanding Patient Engagement Trends in Anxiety Disorder Clinical Research Starting soon
Assessing Patient Engagement in Keratoconus Clinical Research Starting soon
Exploring Acne Treatments Through Clinical Research Participation Starting soon

Other trials for the same condition

Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product Enrolling by invitation
Prospective Decision Impact Trial of KidneyIntelX Active, not recruiting
Real World Evidence Clinical Utility Study of KidneyIntelX Recruiting
Atrasentan in Patients With Proteinuric Glomerular Diseases Active, not recruiting
A Long-Term Follow-Up Study of Participants Exposed to REACT Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06101901 on ClinicalTrials.gov ↗ ← All trials in the USA